​

Funding Round

Series C - Pulmocide

Series C - Pulmocide

Investment Firm

Overview

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

Announced Date

Dec 06, 2022

Funding Type

Series C

Highlights

Location

Europe

Social

Investor Lead

Vivo Capital

Vivo Capital

Vivo Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Pictet Alternative Advisors

Pictet Alternative Advisors

No designation

Participant Investors

11

Investor Name
Participant InvestorAsahi Kasei Pharma
Participant InvestorF-Prime Capital
Participant InvestorSV Health Investors
Participant InvestorIP Group
Participant InvestorVivo Capital

Round Details and Background

Pulmocide raised $52000000 on 2022-12-06 in Series C

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
May 27, 2021
Series C - Pulmocide
9-92.0M
Dec 06, 2021
Grant - Pulmocide
1-3.5M
Dec 06, 2022
Series C - Pulmocide
12-52.0M
Nov 26, 2013
Series A - Pulmocide
4-27.6M

Recent Activity

There is no recent news or activity for this profile.